Attendee search 

Single cell multi-omics company to eradicate cancer

Top American medical device company

.

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.

see company website

PepLib is rethinking peptide drug discovery: a revolutionary platform technology company with a proprietary peptide library, unique screening capabilities, and robust internal drug development programs. PepLib’s novel peptide technology platform uses cyclic peptides to encode and compress half of a billion sequences, including complete peptide libraries up to pentapeptides (ZSenithFive™). PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins. Intelligently designed, individually isolated and packed peptides in HTS well format support functional assays, including cell-based assay and in vivo assay. PepLib has validated the efficiency of the platform on the well-studied PD-1/PD-L1 model and through their partnerships with multiple pharmaceutical companies and internal development programs in oncology, pain, metabolic disorders, and antimicrobials/antivirals, including COVID. Formed by leading scientists in peptide chemistry and biosynthesis with a combined 75 years of biopharmaceutical R&D experience, PepLib hopes to leverage its innovative platform to advance peptide drug discovery for the global biopharmaceutical community.

We are leaders in therapeutic target discovery and RNA-targeted therapies in Cardiovascular Disease (CVD). Our technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
We have developed a rich pipeline of therapeutics, including RNAi and NCE's for heart failure, cardiotoxicity, cardiac regeneration and rare cardiometabolic disease.